June 24, 2009. I have scrutinized FDA policies, processes, and decisions as a Congressional investigator and in my current position.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony on Seroquel, Zyprexa and Geodon
June 9, 2009. NCHR was disappointed by the quality of the research presented for these three drugs, and the FDA’s failure to clearly present those shortcomings in this meeting.
Read More »NCHR Letter to U.S. Senator Charles Grassley (Ranking Member of the Finance Committee) supporting S. 301, the “Physician Payments Sunshine Act of 2009”
May 29, 2009. The Physician Payments Sunshine Act would bring much needed transparency to the often secretive financial relationships between medical products manufacturers and health care professionals.
Read More »NCHR Letter to U.S. Senator Dianne Feinstein (CA) supporting S. 925, the “Safe Baby Products Act of 2009”
May 19, 2009. On behalf of the National Research Center for Women & Families, I am writing to express our strong support for S. 925, the “Safe Baby Products Act of 2009,” which would examine cosmetics and personal care products marketed to children for impurities.
Read More »NCHR Letter to U.S. Sentor Kirsten Gillibrand (NY) Supporting the “Safe Baby Products Act of 2009”
May 19, 2009. On behalf of the National Research Center for Women & Families, I am writing to express our strong support for S. 925, the “Safe Baby Products Act of 2009,” which would examine cosmetics and personal care products marketed to children for impurities.
Read More »